Syros to acquire New Jersey biotech Tyme Technologies Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come. M&A activity picks up among life sciences firms (“Syros”) and “FOR” all other matters to be voted upon at the Company’s upcoming Special Meeting of Stockholders (the (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Glass Lewis”) and Institutional Shareholder Services Inc. ![]() (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. 07, 2022 (GLOBE NEWSWIRE) - Tyme Technologies, Inc. ![]() Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and TymeīEDMINSTER, N.J., Sept. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20 (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. 15, 2022 (GLOBE NEWSWIRE) - Syros Pharmaceuticals, Inc. Combined Company to Trade on Nasdaq Under Ticker “SYRS” - Syros Announces 1-for-10 Reverse Stock Split of Common Stock - CAMBRIDGE, Mass. Syros and Tyme Technologies Announce Stockholder Approval of Merger William White on InvestorPlace | September 16, 2022 We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them! Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday This is my first DD ever, sorry if it sucks yall.Below are the latest news stories about TYME TECHNOLOGIES INC that investors may wish to consider to help them evaluate TYME as an investment opportunity. My positions: 110 shares at 2.06 avg (not much but I'm poor) You can see their presentation about it on their site.Īlso: This has a price target of $8-9 from numerous analysts. Something to note: TYME-18 treatment resulted in 11/12(91.6%) of established tumors resolving completely in mice, compared with ~16x mean growth in control treatment. If Tyme has good news to present, this stock will easily moon as this could change our view of cancer forever. ![]() With this in mind, why now? They are presenting today through Sunday at the American Society of Clinical Oncology 2021, and have already been in the 2nd and 3rd stage for a lot of their trials. Keep in mind I am not an expert, but this is what I am getting from researching this. ![]() In layman's terms, instead of targeting the cancer itself, they create an environment in your body that cancer can't live in (which eventually kills it). It's also important to note that they are targeting ADVANCED cancers, such as pancreatic cancer, which could be huge if they are successful. Instead of using targeted therapy for cancers, Tyme takes advantage of cancer cell's innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's immune system. Tyme Technologies (TYME), is a biotech company that focuses on developing cancer therapies. Hello everyone, you guys have helped me a lot recently so I wanted to share this with you before it's too late.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |